Dual-Enzyme Encapsulated Porous Nanocapsules for Lysosome-Targeted, Hypoxia-Amplified Cancer Therapy

Area of Science:

• Biomaterials Science
• Nanotechnology
• Cancer Therapeutics

Background:

• Glucose oxidase (GOx) and horseradish peroxidase (HRP) enzymes can be used to target cancer cells.
• Tumor hypoxia is a key factor in cancer progression and treatment resistance.
• Nanoparticle drug delivery systems offer potential for targeted cancer therapy.

Purpose of the Study:

• To synthesize and characterize hollow, porous organic nanocapsules (HPOCs) for co-delivery of GOx and HRP.
• To investigate the efficacy of HPOCs loaded with GOx and HRP in inducing cancer cell death under hypoxic conditions.
• To evaluate the potential of this dual-enzyme system for synergistic, hypoxia-amplified cancer therapy.

Main Methods:

• HPOCs synthesized using an inverse mini-emulsion technique with functionalized diamine and tetracarbaldehyde precursors.
• Confocal microscopy used to confirm co-encapsulation and lysosomal localization of BODIPY-labeled GOx and Cy5-labeled HRP within HPOCs.
• In vitro evaluation of HPOCs' biocompatibility and therapeutic efficacy on cancer cells under hypoxic conditions.

Main Results:

• HPOCs (∼145 nm diameter) successfully co-encapsulated GOx and HRP, acting as size-exclusion membranes.
• Confocal studies confirmed enzyme encapsulation and lysosomal localization.
• HPOCs demonstrated excellent biocompatibility and induced significant cancer cell apoptosis (∼75%) and G2/M cell cycle arrest under hypoxia, with negligible effects from control nanocapsules.

Conclusions:

• The developed HPOCs provide an effective platform for co-delivering GOx and HRP.
• The synergistic action of GOx and HRP within HPOCs significantly enhances cancer cell death by amplifying tumor hypoxia.
• This dual-enzyme loaded nanocapsule system represents a promising strategy for hypoxia-amplified cancer therapy.